# Tenon Medical, Inc.

**TNON**

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001560293

# None

### No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $10.8M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data<br>not computable: dilution, distress, fortress balance sheet |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 27, 2026<br>226 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026 |
| **Last close** | $1.66<br>2026-11-06; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 27, 2026*

Medical, Inc. ("we" or the "Company") was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. We are a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. We currently offer two systems to treat a diseased sacroiliac joint (the "SI Joint"). We have developed The Catamaran®? SI Joint Fusion System ("The Catamaran System") that offers a novel, less invasive approach to the SI Joint using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. We received U.S.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 43.4** | | | | | | |
| Gross profitability | 21.9% | 32.3% | | 62.0 | 365 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (17.6%) | (6.6%) | | 24.8 | 802 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 4* | | | | | | |
| **Solvency, sleeve percentile 75.1** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |
| Altman Z double-prime | (29.53) | (0.37) | | 80.0 | 747 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *interest expense must exceed $100,000* | | | | | | |
| Current ratio | 2.11x | 2.94x | | 70.2 | 828 | 2025-12-31 |
| **Growth and financing, sleeve percentile 30.5** | | | | | | |
| Revenue growth, three-year compound | 78.7% | 10.0% | | 7.2 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 3* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | (1.0%) | 2.2% | | 53.7 | 696 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 1.7 months |
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-06 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (90.3%) | (2.1%) | 3 |
| Distance from 52-week high | (96.4%) | (30.5%) | 2 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | not computable | 0.29 | |
| Sales to price | not computable | 0.30 | |
| Composite equity issuance, five years | not computable | 21.4% | |
| Relative strength against the sector, log excess return | (2.50) | (0.19) | 3 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | pass |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $1.7M |
| Operating cash flow, four quarters | -$11.8M |
| Months of runway | 1.7 |
| Days since last periodic filing | 87 (10-Q received Aug 13, 2026) |
| Median daily dollar volume, 63 sessions | $774,184 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $2.4M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 2 | assets | us-gaap:Assets | $10.8M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 3 | net income | us-gaap:NetIncomeLoss | -$12.6M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$10.7M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 5 | assets | us-gaap:Assets | $9.8M | 2024-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 6 | current assets | us-gaap:AssetsCurrent | $6.8M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 7 | current liabilities | us-gaap:LiabilitiesCurrent | $3.2M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 8 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$81.3M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 9 | operating income | us-gaap:OperatingIncomeLoss | -$12.8M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 10 | book equity | us-gaap:StockholdersEquity | $5.0M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 11 | liabilities | us-gaap:Liabilities | $5.7M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 12 | operating income | us-gaap:OperatingIncomeLoss | -$15.7M | 2023-12-31 | 2025-03-26 | 10-K | 25-002734 |
| 13 | interest expense | us-gaap:InterestExpense | $21,000 | 2023-12-31 | 2024-03-29 | 10-K | 24-028010 |
| 14 | revenue | us-gaap:Revenues | $3.9M | 2025-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 15 | revenue | us-gaap:Revenues | $3.3M | 2024-12-31 | 2026-03-27 | 10-K | 26-035707 |
| 16 | revenue | us-gaap:Revenues | $2.9M | 2023-12-31 | 2025-03-26 | 10-K | 25-002734 |
| 17 | revenue | us-gaap:Revenues | $691,000 | 2022-12-31 | 2024-03-29 | 10-K | 24-028010 |
| 18 | assets | us-gaap:Assets | $6.3M | 2023-12-31 | 2025-03-26 | 10-K | 25-002734 |
| 19 | assets | us-gaap:Assets | $11.1M | 2022-12-31 | 2024-03-29 | 10-K | 24-028010 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.